Biotechnology company enGene Holdings Inc (Nasdaq: ENGN) declared on Wednesday that it has reached its target enrollment of 100 patients for the pivotal cohort of the Phase 2 LEGEND trial evaluating detalimogene voraplasmid in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS).
An update from the pivotal cohort is expected in the fourth quarter of 2025, with a Biologics License Application submission now planned for the second half of 2026.
Detalimogene, developed with enGene's Dually Derivatized Oligochitosan (DDX) platform, is a non-viral gene therapy designed to trigger a localised anti-tumour immune response. The therapy has received Regenerative Medicine Advanced Therapy and Fast Track designations from the U.S. Food and Drug Administration.
The multi-cohort LEGEND trial is also enrolling patients across the USA, Canada, Europe and the Asia-Pacific region in additional cohorts, including BCG-naïve and BCG-exposed NMIBC patients with CIS, as well as those with papillary-only disease.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Formation Bio acquires worldwide rights to FHND5032 from CTFH
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
Almirall receives China approval for Seysara to treat moderate-to-severe acne